New York, NY— December 15, 2025, Lange Neurology, PC has been designated a trial site by Immunovant, Inc. for its Phase IIb study of IMVT-1402 treatment in adults. Immunovant, Inc. is a clinical-stage immunology company, dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti FCrn technology, the company develops innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.

“Anti FCrn therapy is a remarkable advancement in the treatment of myasthenia gravis,” Dr. Lange said. “Our hope is that IMVT-1402 will improve symptom control while providing a treatment that is less intrusive to out-patients’ lives while having an excellent safety profile.”